Welcome to our dedicated page for Vivos Therapeutics SEC filings (Ticker: VVOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking FDA milestones, dentist network expansion, and royalty streams in Vivos Therapeutics filings can feel like navigating medical jargon and legalese at once. Whether you are searching for “Vivos Therapeutics insider trading Form 4 transactions” before earnings or just wondering how the latest 8-K affects competitive positioning, the details are scattered across hundreds of pages.
Stock Titan resolves that pain. Our platform delivers AI-powered summaries that translate dense disclosures into clear insights, then ties every data point back to what moves VVOS shares. Need the “Vivos Therapeutics quarterly earnings report 10-Q filing” distilled into key revenue shifts? Looking for “Vivos Therapeutics annual report 10-K simplified” to see R&D spend or FDA regulatory pathways? We surface it instantly, alongside
- real-time alerts for “Vivos Therapeutics Form 4 insider transactions real-time”
- side-by-side comparisons of each “Vivos Therapeutics proxy statement executive compensation”
- concise breakdowns of “Vivos Therapeutics 8-K material events explained”
Here you will find every form the company submits—10-K, 10-Q, 8-K, S-1, Section 16 filings—plus AI commentary that answers the exact questions professionals ask, like “understanding Vivos Therapeutics SEC documents with AI” or seeking a quick “Vivos Therapeutics earnings report filing analysis.” Monitor “Vivos Therapeutics executive stock transactions Form 4,” follow segment revenue trends, and assess how new clinical data may reshape growth projections, all without wading through technical text. Complex filings, made clear—so you can focus on decision-making, not document hunting.
Michael C. Skaff filed an initial Form 3 statement of beneficial ownership for Vivos Therapeutics (VVOS), reporting his position as a 10% owner. The filing details significant holdings through two investment vehicles:
Through V-CO Investors LLC:
- 514,498 shares of common stock
- Pre-Funded Warrant for 2,705,768 shares (exercise price: $0.0001, expires 2034)
- Common Stock Purchase Warrant for 3,220,266 shares (exercise price: $2.204, expires 2029)
Through V-Co Investors 2 LLC:
- 828,000 shares of common stock
- Pre-Funded Warrant for 725,258 shares (exercise price: $0.0001, expires 2035)
- Common Stock Purchase Warrant for 2,329,886 shares (exercise price: $2.23, expires 2030)
Skaff serves as Managing Director of SP Manager LLC, which manages both investment vehicles. He disclaims beneficial ownership except for his pecuniary interest.
FAQ
What is the current stock price of Vivos Therapeutics (VVOS)?
What is the market cap of Vivos Therapeutics (VVOS)?
What is the core focus of Vivos Therapeutics Inc?
How does the company generate its revenue?
What is the Vivos System?
Who are the primary beneficiaries of Vivos Therapeutics' services?
What distinguishes Vivos Therapeutics from traditional CPAP therapies?
How does Vivos Therapeutics integrate with the healthcare ecosystem?
What market challenges does Vivos Therapeutics face?
How does Vivos Therapeutics demonstrate industry expertise?
